In one paragraphArticle in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Emma Elizabeth Sabu KattumanDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Venkatesh KatariDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Somayeh DarziDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Ivana de la SernaDepartment of Cell and Cancer Biology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Charles K ThodetiDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Sailaja ParuchuriDepartment of Physiology and Pharmacology, The University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA. Sailaja.Paruchuri@UToledo.edu.ORCID http://orcid.org/0000-0003-2377-4327 Funding
Integration of Leukotriene and Prostaglandin Receptor Signaling in Mast Cell Activation and Pulmonary Inflammation during AsthmaR01AI144115 · NIAID · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI PARUCHURI, SAILAJA · 2019 to 2023
$1.8MNovel cysteinyl leukotriene receptor signaling in regulating cellular, and molecular events in lung inflammationR01HL178459 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI Sailaja Paruchuri · 2025 to 2026
$1.1MAmerican Heart Association (American Heart Association, Inc.) 25PRE1373953American Heart Association (American Heart Association, Inc.) 25TPA1473648American Heart Association (American Heart Association, Inc.) AHA-TPA-971237NHLBI NIH HHS R01 HL178459NIAID NIH HHS R01 AI144115U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL178459U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01 AI144115
6 · The paper itselfAbstract
Cutaneous melanoma remains the most lethal skin cancer due to profound tumor heterogeneity and the frequent development of resistance to current therapies. Here, we identify the cysteinyl leukotriene receptor 1 (CysLT
Indexed as
Adaptor Proteins, Signal TransducingMelanomaReceptors, LeukotrieneSkin NeoplasmsTranscription FactorsAnimalsAutocrine CommunicationCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemMiceSignal TransductionYAP-Signaling ProteinsAdaptor Proteins, Signal Transducingleukotriene D4 receptorReceptors, LeukotrieneTranscription FactorsYAP1 protein, humanYAP-Signaling Proteins
Identifiers
PMID42498732
PMCPMC13503276
What OpenQuestion holds
Textmetadata
Read underepoch 390